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Zinc Deficiency–Associated Dermatitis in Infants During
a Nationwide Shortage of Injectable Zinc —
Washington, DC, and Houston, Texas, 2012–2013
Duke Ruktanonchai, MD1, Michael Lowe, PhD1, Scott A. Norton, MD2, Tiana Garrett, PhD1, Lamia Soghier, MD3, Edward Weiss,
MD4, June Hatfield, MS3, Jeffrey Lapinski, MS3, Steven Abrams, MD4, Wanda Barfield, MD5 (Author affiliations at end of text)

Injectable zinc, a vital component of parenteral nutrition
(PN) formulations, has been in short supply in the United
States since late 2012. In December 2012, three premature
infants with cholestasis hospitalized in Washington, DC,
experienced erosive dermatitis in the diaper area and blisters on
their extremities, a condition that can be associated with zinc
deficiency (1). All three infants were receiving PN because they
had extreme cholestasis and were unable to be fed by mouth or
tube. The PN administered to each infant was zinc deficient.
Injectable zinc normally is added to PN for premature or
medically compromised infants (e.g., those with cholestasis)
by the hospital pharmacy because the amount of zinc needed
by each patient differs; however, the pharmacy had run out of
injectable zinc. No alternatives were available; other preparations of parenteral trace elements either contained insufficient
zinc to meet infants’ requirements or had the potential to
cause trace element toxicity in infants with cholestasis (2). The
dermatitis of one infant resolved after the patient was able to
take nutrition by mouth. The other two infants were found to
have low serum zinc levels. In January 2013, CDC was notified of four additional cases of zinc deficiency among infants
with cholestasis who received zinc-deficient PN in a hospital
in Houston, Texas. In collaboration with the Food and Drug
Administration (FDA), the two hospitals obtained emergency
shipments of injectable zinc. No additional cases were reported.
Current injectable zinc supplies have been increasing as FDA
collaborates with pharmaceutical companies to import emergency supplies. FDA is working to establish temporary backup
sources should future shortages occur.
On December 18, 2012, three cases of zinc deficiency disorder in premature infants were diagnosed in Washington, DC.
Among the three infants, two were born at 24 weeks’ gestation,
and one was born at 29 weeks’ gestation. Birth weights ranged
from 551 g to 734 g (Table). The hospital caring for the infants
had exhausted its supply of injectable zinc in November 2012.
Infants typically receive injectable zinc and other trace elements
as part of PN. Because of extreme cholestasis and prematurity
in all three infants, they were unable to receive zinc through
oral or enteral feedings. Among cholestatic infants, other
preparations of zinc-containing parenteral trace elements might
cause trace element toxicity; therefore, no alternatives to the

injectable zinc supplements were available. On January 3,
2013, the District of Columbia Department of Health and
CDC began case investigations. For this investigation, a case
of zinc deficiency disorder was defined as an infant receiving
zinc-deficient PN who had either a below-normal serum zinc
level (<70 µg/dL) or dermatitis consistent with zinc deficiency
disorder. The objectives of the investigation were to 1) identify
and describe cases of zinc deficiency disorder among infants at
greatest risk for zinc deficiency, including those who were born
at <37 weeks’ gestation, those weighing <1,500 g at birth, and
those with chronic or permanent gastrointestinal dysfunction;
2) investigate the cause of the injectable zinc shortage; and
3) describe the need to monitor symptoms of micronutrient
deficiency during micronutrient shortages.
After consulting with CDC, on January 10, 2013, the
American Academy of Pediatrics (AAP) informed its members,
which include approximately 3,000 neonatologists and 800
neonatal intensive care units nationwide, of the injectable
zinc shortage. The members were asked to report to AAP and
their respective state health department if their hospitals were
experiencing a critical shortage of zinc. AAP compiled and forwarded all responses to CDC. On January 21, a neonatologist
in Houston, Texas, reported four additional cases of zinc deficiency disorder to CDC. Among these four infants, two were
born at gestational ages >37 weeks; one was born at 33 weeks,
and one was born at 25 weeks. All four infants had cholestasis. Birth weights of these four infants ranged from 690 g to
2,950 g (Table). The Houston hospital also had exhausted its
supplies of injectable zinc in November 2012. By January 22,
2013, a total of 17 hospitals in 10 states had reported shortages of zinc and other micronutrients. No additional cases of
zinc deficiency disorder were identified. By the end of January,
FDA was able to facilitate emergency shipment of injectable
zinc to all 17 hospitals.
Each of the seven infants experienced zinc deficiency disorder
after receiving zinc-deficient PN as a result of the nationwide
shortage. The time from initiation of PN to diagnosis of zinc
deficiency disorder ranged from 4 to 34 weeks; the exact number of weeks each infant was on zinc-deficient PN is unknown.
Six patients were characterized as having low serum zinc levels
(range:14–56 µg/dL [normal: 70–120 µg/dL]) and low alkaline
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TABLE. Seven infants with physician-diagnosed zinc deficiency disorder, by selected characteristics — Washington, DC, and Houston, Texas,
2012–2013

Patient Sex

Gestational Birth
age (wks) weight (g) Cholestasis

Race/
Ethnicity

PN duration
Serum
before
Serum
alkaline
Received
diagnosis zinc level phosphatase
PN
Dermatitis
(wks)
(µg/dL)* level (U/L)†

Bacterial
infection

Infant
death

1

M

24

734

Yes

Black, non-Hispanic

Yes

Yes

10

NA

192

No

No

2
3
4
5
6
7

M
F
M
M
F
M

24
29
37
25
37
33

673
551
2,950
690
2,620
1,599

Yes
Yes
Yes
Yes
Yes
Yes

Black, non-Hispanic
Black, non-Hispanic
White, Hispanic
White, non-Hispanic
White, Hispanic
Black, Hispanic

Yes
Yes
Yes
Yes
Yes
Yes

Yes
Yes
Yes
Yes
Yes
No

15
10
18
34
5
4

14
56
16
41
25
34

62
32
74
73
110
92

No
No
No
Yes§
Yes¶
Yes**

No
No
No
Yes
Yes
No

Abbreviations: PN = parenteral nutrition; NA = not available.
* Lowest serum zinc level measured by laboratory testing; normal range = 70–120 μg/dL.
† Lowest serum alkaline phosphatase level measured by laboratory testing; normal range = 150–420 U/L.
§ Staphylococcus aureus.
¶ Methicillin-resistant Staphylococcus aureus.
** Escherichia coli and Kluyvera ascorbata.

phosphatase levels (range: 32–125 U/L [normal: 150–420 U/L]).
Alkaline phosphatase levels typically are high in patients with
cholestasis, but the zinc deficiency disorder in these infants
resulted in low alkaline phosphatase levels. The serum zinc
level for the first patient was not measured because suspicion
of zinc deficiency disorder occurred after the infant had taken
oral feedings containing zinc and the dermatitis had resolved.
All seven infants had cholestasis. Six of the seven had dermatitis consistent with zinc deficiency disorder, and three experienced bacterial infections. One infant experienced recurrent
sepsis and liver failure before receiving zinc-deficient PN. This
infant did not have dermatitis but had a low serum zinc level
(Table). The infant died, and an autopsy was not performed.
It is uncertain whether zinc deficiency disorder had a role in
his death. After an emergency shipment of zinc was received by
two hospitals, the remaining six infants received zinc in their
PN, and all six infants improved clinically. Zinc and alkaline
phosphatase levels returned to normal ranges, and the infants’
skin lesions resolved. Five of the six infants were discharged
home. One infant remained hospitalized for 6 months for
treatment of conditions unrelated to zinc deficiency disorder;
that infant died in October 2013 from conditions unrelated
to zinc deficiency disorder.
According to FDA, only two domestic manufacturers’ injectable zinc compounds are used in PN (American Regent and
Hospira, Inc.). In fall 2012, American Regent informed FDA
that it would be experiencing shortages of multiple chemicals,
including zinc sulfate, because of delays in manufacturing.
These delays resulted from drug quality concerns identified by
the company, which included problems of particulate matter
in the injectable products. FDA then contacted Hospira to
determine whether they could meet the increase in zinc demand.
Hospira representatives stated that the company was operating
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at maximum capacity and was unable to meet the increased
demand; thus, the shortage continued to worsen in early
January 2013. American Regent was able to release injectable
zinc sulfate on January 22, but shortages continued. Hospira
planned to release injectable zinc sulfate again by the end of
2013. One foreign manufacturer, Laboratoire Aguettant, and its
authorized U.S. distributor, Baxter Healthcare, in conjunction
with the FDA, have initiated temporary importation of an injectable zinc solution into the U.S. market to address this shortage.
FDA is continuing to work with American Regent and Hospira
to expedite release of injectable zinc sulfate. Information for
health-care providers regarding the zinc shortages and expected
release dates of new supplies of injectable zinc is provided by
FDA on its drug shortage website (http://www.fda.gov/drugs/
drugsafety/drugshortages/ucm050792.htm). Finally, FDA is
working with pharmaceutical companies to establish temporary
backup sources for micronutrients should future shortages occur.
When FDA uses regulatory discretion to allow a company to
import a drug temporarily during a shortage, FDA ensures that
the overseas manufacturing facility meets FDA quality standards
and that its products (in terms of formulation and labeling) do
not present undue risks for patients.
Editorial Note

Zinc is an essential trace element that functions as a cofactor
for certain enzymes involved in metabolism and cell growth
(2,3); zinc supports immune function, protein metabolism,
development of the gastrointestinal tract, and genetic processes
(3). Acute zinc deficiency disorder is characterized by dermatitis around the limbs and body orifices, diarrhea, and impaired
immune function, whereas chronic zinc deficiency disorder can
lead to liver or kidney failure (2). A rare genetic disorder, acrodermatitis enteropathica, shares the same clinical manifestations
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What is already known on this topic?
Nationwide shortages of parenteral micronutrients have
continued to occur in recent years. These shortages can lead to
clinically significant micronutrient deficiencies among patients
who depend on prolonged parenteral nutrition. Premature
infants are especially vulnerable, and certain micronutrient
deficiencies can be lethal.
What is added by this report?
The nationwide shortage of injectable zinc that began in late
2012 led to seven reported cases of zinc deficiency disorder in
vulnerable infants. Among these infants, six experienced severe
dermatitis, and three experienced invasive bacterial infections.
The Food and Drug Administration is now temporarily permitting the importation and sale of an injectable zinc product.
What are the implications for public health practice?
Hospitals with limited stocks of injectable zinc should consider
reserving supplies for infants with the highest risk for deficiency
(e.g., those who are premature [born at <37 weeks’ gestation] or
have very low birth weight [<1,500 g] and those with chronic or
permanent gastrointestinal dysfunction). If shortages occur,
monitoring patients on parenteral nutrition for signs and
symptoms of micronutrient deficiencies is crucial.

as acute zinc deficiency disorder but is a metabolic disorder of
zinc absorption. Zinc is a standard component in PN. Premature
infants administered PN require 400 µg/kg/body weight/day
of zinc to maintain serum levels and promote growth, whereas
200 µg/kg/body weight/day of zinc is sufficient for full-term
infants on PN (4). Additionally, PN might be needed for prolonged periods for very low birth weight infants (<1,500 g) and
infants with chronic gastrointestinal dysfunction.
Studies have reported progressively decreasing serum zinc
levels among infants on zinc-deficient PN, particularly premature infants and low birth weight infants (3,5). Although zinc
deficiency disorder can have serious health implications among
all age groups, infants are particularly vulnerable because their
systemic zinc reserves are not fully developed and they are
totally dependent on breast milk or formula. Therefore, the
American Society for Clinical Nutrition recommends adding
injectable zinc to PN for all infants and children, with priority
for those who are premature, have low birth weight, or have
chronic gastrointestinal dysfunction (4).
Zinc deficiencies among infants are difficult to identify for
multiple reasons, including nonspecific signs and symptoms. The
most common signs of zinc deficiency disorder include dermatitis and growth impairment, which can be attributed to multiple
causes. Zinc deficiency disorder–associated dermatitis, which
is a physical manifestation, is present in only the most severe
cases. For premature infants, withdrawl of the amount of blood
required to measure the serum zinc level might compromise the

health of the infant; therefore, routine testing is not performed,
which might explain, in part, why no other cases were reported.
Physicians who prescribe PN should recognize the potential
risks for micronutrient deficiency, including zinc deficiency,
among premature infants who require increased amounts or are
unable to receive adequate doses. During shortages, clinicians
might need to reserve micronutrients for the most vulnerable
populations. According to FDA, shortages also are ongoing
for other PN micronutrient components (e.g., selenium,
chromium, and copper); FDA is working with manufacturers
to prioritize which micronutrients to produce and to identify
other sources for the micronutrients. Until the manufacture
of these micronutrients increases, shortages will continue.
Hospitals with limited stocks of injectable zinc should consider
reserving available supplies for infants with the highest risk for
deficiency. Whenever PN without the standard micronutrients
is administered to patients, either as a result of shortages or
other considerations, monitoring for signs and symptoms
of micronutrient deficiencies is recommended. Health-care
providers should always consider the specific clinical situation
when applying these guidelines for individual clinical care.
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